Eli Lilly and Company has made another move in bolstering its presence in genetic diseases by driving a $139m series B financing for Jaguar Gene Therapy and its pipeline that includes potential one-time treatments for type 1 diabetes and autism.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?